Actively Recruiting
Phase 1 Study to Understand How PF-07328948 is Processed in Adults With and Without Liver Impairment Single Dose Oral Tablet in Adults 18 to 75 Years
Led by Pfizer · Updated on 2026-07-23
26
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how decreased liver function affects the way the body processes the medicine PF-07328948. The study involves adults aged 18 to 75 years with varying degrees of liver function, including healthy individuals and those with mild, moderate, or severe liver impairment. The goal is to understand if liver function changes the processing of this medicine in the body. Participants will receive a single oral dose of PF-07328948 tablet at the study clinic. Four groups are studied in parallel one with no liver impairment, and three with mild, moderate, or severe hepatic impairment. After taking the dose, participants will stay at the clinic for about six days for monitoring and testing. During the clinic stay, the study team will observe participants for treatment experience and collect blood samples at multiple time points to measure levels of PF-07328948. This helps assess how the liver function affects drug levels. Safety will be evaluated through adverse event monitoring up to 36 days. The total study duration includes dosing and follow-up assessments to understand the medicines behavior and tolerability.
CONDITIONS
Brief Title
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here